Journal of Cystic Fibrosis vol:8 issue:6 pages:392-399
BACKGROUND: Cystic fibrosis-associated liver disease (CFLD) is the second cause of mortality in CF. The prevalence is estimated to be 26-45%, but sensitive diagnostic tools are lacking. We investigated whether non-invasive liver elastography (Fibroscan) could serve as a screening tool. METHODS: Fibroscan measurements were performed in 66 CF patients. Age-specific cutoff values were determined in a control population (n=59). The measurements were compared to clinical data, biyearly biochemistry and ultrasound. RESULTS: Fibroscan was easy to perform in this patient population. There were 14 patients (21%) with abnormal liver stiffness measurements. Liver stiffness was significantly increased in patients with clinical CFLD (11.2kPa versus 5.1kPa), biochemical CFLD (7.4kPa versus 5.4kPa) or ultrasonographical CFLD (8.2 versus 4.3kPa) (p<0.02 for all). CONCLUSIONS: Fibroscan is an objective measure and is easy to perform in CF patients, even in children and could provide a valuable tool to detect, and quantify CFLD.